Why AbbVie's Stock Sank in the First Half of 2019

Biopharma giant AbbVie (NYSE: ABBV) has had an absolutely regrettable year. Through the course of the first six months of the year, the drugmaker's shares have lost a breathtaking 21.2% of their value, according to data from S&P Global Market Intelligence.